Physician profile
Ronaldo D Factoriza
NPI 1285607275
$1,033.79
in general payments reported to CMS, 2019-2025
17 companies · $79.74 in 2025
The $79.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $13.61 · 2021: $290 · 2022: $63.36 · 2023: $94.77 · 2024: $164 · 2025: $79.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $428.50 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $186.13 | 2019 | |
| Lilly USA, LLC | $100.99 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.10 | 2021 | |
| Pfizer INC. | $47.03 | 2021-2024 | |
| Glaxosmithkline, LLC. | $39.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.61 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $27.99 | 2019 | |
| Argenx US, INC. | $21.73 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $15.08 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.13 | 2024 | Voquezna |
| Amgen INC. | $13.89 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2024 | Zoryve |
| Horizon Therapeutics Plc | $12.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $11.78 | 2019 | |
| Merck Sharp & Dohme LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronaldo Factoriza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.